BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale

Reuters12-09 07:29

BUZZ-<a href="https://laohu8.com/S/FULC">Fulcrum Therapeutics</a> dips after unveiling $150 million share sale

** Shares of drug developer Fulcrum Therapeutics FULC.O fall 1.8% to $12.75 in extended trading

** FULC kicks off public offering of $150 million worth of shares

** Stock closed 46% higher on Monday after FULC unveiled trial data of blood disorder drug

** J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering

** Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes

** 7 of 9 brokerages rate the stock "buy" or higher, one "hold" and one "sell"; median PT $20 - data compiled by LSEG

** As of last close, FULC up 176.4% YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590364342?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 07:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590364342","market":"nz","top_or_hot":-1,"title":"BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> dips after unveiling $150 million share sale</title></head><body><p>** Shares of drug developer Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>FULC.O</span> fall 1.8% to $12.75 in extended trading</p><p>** FULC kicks off public offering of $150 million worth of shares</p><p>** Stock <span>closed</span> 46% higher on Monday after FULC unveiled trial data of blood disorder drug</p><p>** J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering</p><p>** Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes</p><p>** 7 of 9 brokerages rate the stock \"buy\" or higher, one \"hold\" and one \"sell\"; median PT $20 - data compiled by LSEG</p><p>** As of last close, FULC up 176.4% YTD</p><p> (Reporting by Arasu Kannagi Basil in Bengaluru)</p><p> ((ArasuKannagi.Basil@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 07:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> dips after unveiling $150 million share sale</title></head><body><p>** Shares of drug developer Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>FULC.O</span> fall 1.8% to $12.75 in extended trading</p><p>** FULC kicks off public offering of $150 million worth of shares</p><p>** Stock <span>closed</span> 46% higher on Monday after FULC unveiled trial data of blood disorder drug</p><p>** J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering</p><p>** Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes</p><p>** 7 of 9 brokerages rate the stock \"buy\" or higher, one \"hold\" and one \"sell\"; median PT $20 - data compiled by LSEG</p><p>** As of last close, FULC up 176.4% YTD</p><p> (Reporting by Arasu Kannagi Basil in Bengaluru)</p><p> ((ArasuKannagi.Basil@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FULC","symbol_name":"Fulcrum Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE14L:1","article_id":"2590364342","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590364342","pubTimestamp":1765236598,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale** Shares of drug developer Fulcrum Therapeutics FULC.O fall 1.8% to $12.75 in extended trading** FULC kicks off public offering of $150 million worth of shares** Stock closed 46% higher on Monday after FULC unveiled trial data of blood disorder drug** J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering** Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes** 7 of 9 brokerages rate the stock \"buy\" or higher, one \"hold\" and one \"sell\"; median PT $20 - data compiled by LSEG** As of last close, FULC up 176.4% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FULC":"Fulcrum Therapeutics","BK4207":"综合性银行","BK4007":"制药","MNSH":"MNSN HLDGS INC."},"translate_title":"BUZZ-Fulcrum Therapeutics宣布出售1.5亿美元股票后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":0.9,"MNSH":0.9},"content_text":"BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale** Shares of drug developer Fulcrum Therapeutics FULC.O fall 1.8% to $12.75 in extended trading** FULC kicks off public offering of $150 million worth of shares** Stock closed 46% higher on Monday after FULC unveiled trial data of blood disorder drug** J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering** Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes** 7 of 9 brokerages rate the stock \"buy\" or higher, one \"hold\" and one \"sell\"; median PT $20 - data compiled by LSEG** As of last close, FULC up 176.4% YTD (Reporting by Arasu Kannagi Basil in Bengaluru) ((ArasuKannagi.Basil@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590364342","isCrawlerRequest":true}